In Vivo Emergence of a Novel Protease Inhibitor Resistance Signature in HIV-1 Matrix

Protease inhibitors (PIs) are the second- and last-line therapy for the majority of HIV-infected patients worldwide. Only around 20% of individuals who fail PI regimens develop major resistance mutations in protease. We sought to explore the role of mutations in gag-pro genotypic and phenotypic chan...

Descripción completa

Detalles Bibliográficos
Autores principales: Datir, Rawlings, Kemp, Steven, El Bouzidi, Kate, Mlchocova, Petra, Goldstein, Richard, Breuer, Judy, Towers, Greg J., Jolly, Clare, Quiñones-Mateu, Miguel E., Dakum, Patrick S., Ndembi, Nicaise, Gupta, Ravindra K.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society for Microbiology 2020
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7642677/
https://www.ncbi.nlm.nih.gov/pubmed/33144375
http://dx.doi.org/10.1128/mBio.02036-20

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7642677/
https://www.ncbi.nlm.nih.gov/pubmed/33144375
http://dx.doi.org/10.1128/mBio.02036-20

Ejemplares similares